GAITHERSBURG, Md., July 02, 2024. artesian Therapeutics, Inc. (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - PHARMABIZ.COM - A la Une - 04/Jul 00:00
Cartesian Therapeutics doses first patient in phase 2 clinical trial of Descartes─08 to treat systematic lupus erythematosus
Cartesian Therapeutics, Inc, a clinical─stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, announced that the first patient has been dosed in its phase 2 open─label clinical trial
Articles similaires
Immutep announces positive results from TACTI─003 phase IIb trial of efti in combo with Keytruda to treat HNSCC patients with negative PD─L1 expression
pharmabiz.com - 00:00
Immutep Limited (Immutep), a clinical─stage biotechnology company developing novel LAG─3 immunotherapies for cancer and autoimmune disease,...
Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg
drugs.com - 02/Jul 04:07
DAEJEON, South Korea, July 2, 2024. PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing...
Approval for the First Dose Cohort in Phase 1a/b Clinical Trial of PMC-309 in Patients with Advanced or Metastatic Solid Tumors
drugs.com - 09/Jul 00:07
DAEJEON, South Korea, July 8, 2024. PharmAbcine Inc., a clinical-stage biotech company focusing on next-generation antibody therapeutics, announced...
Imugene delivers first Aussie bile tract cancer trial dose
thewest.com.au - 10/Jul 06:42
Imugene has dosed its first of 10 Australian patients with its potent “VAXINIA” therapy as part of its phase-one bile tract cancer trial being...
Worldwide Clinical Trials - USA: Senior Clinical Research Associate* - CAR-T and Cell Therapy
pharmiweb.com - 00:00
Competitive: Worldwide Clinical Trials - USA: Who we are Worldwide Clinical Trials (Worldwide), a leading global contract research organization...
Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals
zacks.com - 12:39
Immutep (IMMP) jumps 15% on positive results from a late-stage study evaluating its candidate, efti, in combination with Keytruda to treat first-line...
Verastem (VSTM) Begins Dosing in Solid Tumors Study in China
zacks.com - 15:42
Verastem (VSTM) doses the first patient in a phase I/II study conducted by GenFleet Therapeutics, evaluating KRAS G12D inhibitor, GFH375/VS-7375 in...
Expanded HyBryte Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
drugs.com - 10/Jul 01:07
PRINCETON, N.J., July 9, 2024 /PRNewswire/ -- Soligenix, Inc., (Soligenix or the Company), a late-stage biopharmaceutical company focused on...
Les derniers communiqués
-
Aucun élément